Skip to content

Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home

Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home in Metabolic Control of People With Diabetes Mellitus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01475422
Enrollment
91
Registered
2011-11-21
Start date
2011-09-30
Completion date
2012-03-31
Last updated
2011-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

The self-monitoring of capillary blood glucose is part of the package of interventions in diabetes mellitus and an effective therapeutic strategy for the adequate control of the disease; and the continuing education of people with DM is recognized as one of the goals to delay the complications arising from chronic disease and alleviate the symptoms of hypoglycemia and hyperglycemia.

Detailed description

This study aims to evaluate the effects of educational intervention on self-monitoring of capillary blood glucose in metabolic control, knowledge and attitude in two groups of patients with diabetes mellitus: a group of diabetic patients who participate in the Self-Monitoring of Capillary Blood Glucose at Home Program and receive educational interventions (Intervention Group - G1) and a group of diabetic patients who participle in the Self-Monitoring of Capillary Blood Glucose at Home Program and receive conventional treatment (Control Group - G2). As an educational tool in diabetes will be used Conversation Maps which is considered an interactive program of diabetes education.

Interventions

The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.

BEHAVIORALUsual Care

Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Ages 18 Years and older; * Diagnosis of type 1 and 2 diabetes mellitus; * In follow-up in the Self-Monitoring of Capillary Blood Glucose at Home Program; * Have cognitive conditions that enable participation (minimum ability of users to understand issues of data collection instruments, observation of the researcher and/or of the caregivers).

Exclusion criteria

* Patients with gestational DM; * Patients with DM who are not located; * Those who die in the proposed period for the research; * Those who dropout the Self-Monitoring of Capillary Blood Glucose at Home Program; * Those who report difficulties to participate of the study due to work and those with amaurosis; * Used Conversation Maps as an educational tool.

Design outcomes

Primary

MeasureTime frameDescription
HbA1cbaseline, 3 and 6 months post interventionChange from baseline in HbA1c at 6 months to less than 7%

Secondary

MeasureTime frameDescription
Diabetes Knowledge Questionnaire - DKN-Abaseline, 3 and 6 months post interventionChange from baseline in DKN-A at six months
Diabetes Attitude Questionnaire - ATT-19baseline, 3 and 6 months post interventionChange from baseline in ATT-19 at six months

Countries

Brazil

Contacts

Primary ContactVívian Saraiva Veras, Principal Investigator
vivianveras@hotmail.com55 16 88074113

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026